An in situ high-throughput screen identifies inhibitors of intracellular Burkholderia pseudomallei with therapeutic efficacy

Keyphrases

• Burkholderia Pseudomallei 100%
• In Situ 100%
• High-throughput Screening 100%
• 5-fluorocytosine 100%
• Therapeutic Efficacy 100%
• Melioidosis 60%
• Burkholderia 60%
• Intercellular Spread 60%
• Select Agent 40%
• Burkholderia Mallei 40%
• Drug Discovery 20%
• Virulence 20%
• Glanders 20%
• High-throughput 20%
• Human Infection 20%
• Antibiotics 20%
• Small Molecules 20%
• Bacterial Count 20%
• Ceftazidime 20%
• Burkholderia Thailandensis 20%
• Cell-based 20%
• Therapeutic Potential 20%
• Cross-species 20%
• Therapeutic Target 20%
• Murine Model 20%
• BSL-2 20%
• FDA-approved Drugs 20%
• Monophosphate 20%
• Antifungal Drugs 20%
• Phenotypic Assay 20%
• Species Validation 20%
• Intracellular Life Cycle 20%
• Phenotypic Screening 20%
• Major Organs 20%
• Flucytosine 20%
• Type VI Secretion System 20%
• Cell-to-cell Spread 20%
• Bacterial Conversion 20%
• 5-fluorouracil (5-FU) 20%
• Fluoroquinolone Analogs 20%
• Selective Activity 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Burkholderia pseudomallei 100%
• Melioidosis 100%
• Burkholderia 100%
• Combination Therapy 100%
• Select Agent 66%
• Burkholderia mallei 66%
• Infection 33%
• Glanders 33%
• Antibiotics 33%
• Ceftazidime 33%
• Quinolone Derivative 33%
• Antifungal Agent 33%
• Burkholderia thailandensis 33%
• Fluorouracil 33%
• Flucytosine 33%
• Fluorouridine 33%
• Drug Discovery 33%

Immunology and Microbiology

• Burkholderia 100%
• Burkholderia pseudomallei 100%
• Burkholderia mallei 66%
• Life Cycle 33%
• Burkholderia thailandensis 33%
• Bacterial Count 33%
• Type VI Secretion System 33%